Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Drug Dev Ind Pharm ; 41(4): 623-30, 2015 Apr.
Article in English | MEDLINE | ID: mdl-24564797

ABSTRACT

Extended release (ER) of water-soluble drugs from hydroxypropylmethylcellulose (HPMC) matrix mini-tablets (mini-matrices) is difficult to achieve due to the large surface area to volume ratio of the mini matrices. Therefore, the aims of this study were to control the release of a water-soluble drug (theophylline) from mini-matrices by applying ER ethylcellulose film coating (Surelease®), and to assess the effects of Surelease®:pore former (Opadry®) ratio and coating load on release rates. Mini-matrices containing 40%w/w HPMC K100M CR were coated with 100:0, 85:15, 80:20, 75:25 or 70:30 Surelease®:Opadry® to different coating weight gains (6-20%). Non-matrix mini-tablets were also produced and coated with 80:20 Surelease®:Opadry® to different coating weight gains. At low coating weight gains, nonmatrix mini-tablets released the entire drug within 0.5 h, while at high coating weight gains only a very small amount (<5%) of drug was released after 12 h. The gel formation of HPMC prevented disintegration of mini-matrices at low coating weight gains but contributed to rupture of the film even at high coating weight gains. As a result, drug release from mini-matrices was slower than that from nonmatrix mini-tablets at low coating weight gains, yet faster at high coating weight gains. An increase in the lag time of drug release from mini-matrices was observed as the concentration of Opadry® reduced or the coating weight gain increased. This study has demonstrated the possibility of extending the release of a water-soluble drug from HPMC mini-matrices by applying ER film coating with appropriate levels of pore former and coating weight gains to tailor the release rate.


Subject(s)
Cellulose/analogs & derivatives , Drug Delivery Systems , Excipients/chemistry , Hypromellose Derivatives/chemistry , Phosphodiesterase Inhibitors/administration & dosage , Polyethylene Glycols/chemistry , Polyvinyl Alcohol/chemistry , Polyvinyls/chemistry , Theophylline/administration & dosage , Cellulose/chemistry , Cellulose/ultrastructure , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/analysis , Delayed-Action Preparations/chemistry , Drug Compounding , Drug Liberation , Gels , Kinetics , Microscopy, Electron, Scanning , Phosphodiesterase Inhibitors/analysis , Phosphodiesterase Inhibitors/chemistry , Porosity , Solubility , Surface Properties , Tablets , Theophylline/analysis , Theophylline/chemistry
2.
Drug Dev Ind Pharm ; 41(1): 70-8, 2015 Jan.
Article in English | MEDLINE | ID: mdl-24134563

ABSTRACT

The particle size of HPMC is a critical factor that can influence drug release rate from hydrophilic matrix systems. Percolation theory is a statistical tool which is used to study the disorder of particles in a lattice of a sample. The percolation threshold is the point at which a component is dominant in a cluster resulting in significant changes in drug release rates. Mini-tablets are compact dosage forms of 1.5-4 mm diameter, which have potential benefits in the delivery of drug to some patient groups such as pediatrics. In this study, the effect of HPMC particle size on hydrocortisone release and its associated percolation threshold for mini-tablets and tablets was assessed. For both mini-tablets and tablets, large polymer particles reduced tensile strength, but increased the drug release rate and the percolation threshold. Upon hydration, compacts with 45-125 µm HPMC particles formed a strong gel layer with low porosity, reducing hydrocortisone release rates. In comparison, faster drug release rates were obtained when 125-355 µm HPMC particles were used, due to the greater pore sizes that resulted in the formation of a weaker gel. Using 125-355 µm HPMC particles increased the percolation threshold for tablets and to a greater extent for mini-tablets. This work has demonstrated the importance of HPMC particle size in ER matrices, the effects of which are even more obvious for mini-tablets.


Subject(s)
Drug Liberation , Lactose/analogs & derivatives , Methylcellulose/analogs & derivatives , Particle Size , Tensile Strength , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacokinetics , Lactose/chemistry , Lactose/pharmacokinetics , Methylcellulose/chemistry , Methylcellulose/pharmacokinetics , Tablets
3.
Drug Dev Ind Pharm ; 39(8): 1167-74, 2013 Aug.
Article in English | MEDLINE | ID: mdl-22540355

ABSTRACT

CONTEXT: Mini-tablets are compact dosage forms, typically 2-3 mm in diameter, which have potential advantages for paediatric drug delivery. Extended release (ER) oral dosage forms are intended to release drugs continuously at rates that are sufficiently controlled to provide periods of prolonged therapeutic action following each administration, and polymers such as hypromelllose (HPMC) are commonly used to produce ER hydrophilic matrices. OBJECTIVE: To develop ER mini-tablets of different sizes for paediatric delivery and to study the effects of HPMC concentration, tablet diameter and drug solubility on release rate. METHODS: The solubility of Hydrocortisone and theophylline was determined. Mini-tablets (2 and 3 mm) and tablets (4 and 7 mm) comprising theophylline or hydrocortisone and HPMC (METHOCEL™ K15M) at different concentrations (30, 40, 50 and 60%w/w) were formulated. The effect of tablet size, HPMC concentration and drug solubility on release rate and tensile strength was studied. RESULTS AND DISCUSSION: Increasing the HPMC content and tablet diameter resulted in a significant decrease in drug release rate from ER mini-tablets. In addition, tablets and mini-tablets containing theophylline produced faster drug dissolution than those containing hydrocortisone, illustrating the influence of drug solubility on release from ER matrices. The results indicate that different drug release profiles and doses can be obtained by varying the polymer content and mini-tablet diameter, thus allowing dose flexibility to suit paediatric requirements. CONCLUSION: This work has demonstrated the feasibility of producing ER mini-tablets to sustain drug release rate, thus allowing dose flexibility for paediatric patients. Drug release rate may be tailored by altering the mini-tablet size or the level of HPMC, without compromising tablet strength.


Subject(s)
Hydrocortisone/administration & dosage , Methylcellulose/analogs & derivatives , Theophylline/administration & dosage , Delayed-Action Preparations , Hydrocortisone/chemistry , Hypromellose Derivatives , Methylcellulose/administration & dosage , Solubility , Tablets , Tensile Strength , Theophylline/chemistry
4.
Drug Dev Ind Pharm ; 39(11): 1690-7, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23078551

ABSTRACT

CONTEXT: Hypromellose (HPMC) has been previously used to control drug release from mini-tablets. However, owing to poor flow, production of mini-tablets containing high HPMC levels is challenging. Directly compressible (DC) HPMC grades have been developed by Dow Chemical Company. OBJECTIVE: To compare the properties of HPMC DC (METHOCEL™ K4M and K100M) with regular (REG) HPMC grades. METHOD: Particle size distribution and flowability of HPMC REG and DC were evaluated. 3 mm mini-tablets, containing hydrocortisone or theophylline as model drugs and 40% w/w HPMC DC or REG were produced. Mini-tablets containing HPMC DC grades were manufactured using a rotary press simulator at forces between 2-4 kN and speeds of 5, 10, 15 or 20 rpm. Mini-tablets containing HPMC REG were produced manually. RESULTS AND DISCUSSION: The improved flowability of HPMC DC grades, which have a narrower particle size distribution and larger particle sizes, meant that simulated large scale production of mini-tablets with good weight uniformity (CV 1.79-4.65%) was feasible. It was not possible to automatically manufacture mini-tablets containing HPMC REG due to the poor flowability of the formulations. Drug release from mini-tablets comprising HPMC DC and REG were comparable. Mini-tablets containing HPMC DC illustrated a higher tensile strength compared to mini-tablets made with HPMC REG. Mini-tablets produced with HPMC DC at different compression speeds had similar drug release profiles. CONCLUSIONS: Production of extended release mini-tablets was successfully achieved when HPMC DC was used. Drug release rate was not influenced by the different HPMC DC grades (K4M or K100M) or production speed.


Subject(s)
Anti-Inflammatory Agents/chemistry , Bronchodilator Agents/chemistry , Excipients/chemistry , Hydrocortisone/chemistry , Methylcellulose/analogs & derivatives , Models, Molecular , Theophylline/chemistry , Anti-Inflammatory Agents/analysis , Bronchodilator Agents/analysis , Chemical Phenomena , Delayed-Action Preparations/chemistry , Drug Compounding , Hydrocortisone/analysis , Hypromellose Derivatives , Kinetics , Mechanical Phenomena , Methylcellulose/chemistry , Microscopy, Electron, Scanning , Particle Size , Quality Control , Solubility , Surface Properties , Tablets , Tensile Strength , Theophylline/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...